Abstract:
The invention relates to an isolated polysaccharide and a composition comprising the polysaccharide for use in treating a neurodegenerative disease.
Abstract:
There is provided polymeric nanoparticles with non-tumour antigen payloads for use in tagging cells for destruction by a subject's immune system and the use thereof for the treatment of cancer. Suitably there is provided a method of treatment comprising administration of nanoparticle comprising a non-tumour protein payload to a subject with cancer, in particular to a cancer cell.
Abstract:
The invention provides a device comprising: at least one biocompatible polymer; and an eutectic composition comprising a first agent and an agent capable of forming a eutectic composition with the first agent; or one or more fatty acids; or one or more fatty alcohols; or one or more fatty amines or combinations thereof. The device can be administered to a subject in need thereof an effective amount of one or more active agents. The at least one biocompatible polymer may be selected from the group comprising poly ethylene-vinyl-acetate, vinyl acetate, silicone, polycaprolactone, polylacticco-glycolic acid, polylactic acid or polyglycolic acid.
Abstract:
A water and solvent free Continuous Manufacturing platform for Nanoparticle Drug delivery systems (COMMAND), such as, self-dispersing solid lipid nanoparticles and proliposomal nanoparticles, and the nanoparticles made by such platform. Byremoving water and solvent from conventional processes, the formation of dry, solvent free self-dispersing solid lipid nanoparticles and dry, solvent free solid proliposomal nanoparticles can be performed using the COMMAND platform.
Abstract:
A method is provided for preparing a material in a fluidic oscillator (10) which comprises a chamber (12) having an inlet (14) and an outlet (16), and at least two feedback arms (18 a,b) through which fluid may pass from the chamber to the inlet to impart an oscillating flow onto a fluid as it is passed through the inlet. The method comprises passing a solution of the material, or a precursor to the material, through the inlet into the chamber; and precipitating the material in the chamber.
Abstract:
The present invention is related to a Fasciola hepatica antigen and vaccine. Specifically, the present invention relates to a Fasciola hepatica antigen comprising a polypeptide, wherein the polypeptide comprises amino acid sequences from Fasciola hepatica, or fragments each thereof. Also disclosed are use of the antigen as a vaccine against Fasciola hepatica infection, and use of the antigen in the manufacture of a vaccine for vaccinating a subject against Fasciola hepatica infection.
Abstract:
The invention relates to peptides, nematicidal compositions, transgenic microorganisms for expressing the peptides and methods of treating plant parasitic nematodes, the method comprising providing either a peptide or a nematicidal composition or a transgenic microorganism for expressing the peptide on or adjacent the plant parasitic nematodes.
Abstract:
The present invention is directed to lactones of the following structural formula for use as precursors of NAD, and their use as nutritional supplements.
Abstract:
The invention is directed to a transdermal delivery device comprising a microneedle array and a reservoir portion, wherein said microneedles are composed of a swellable hydrogel polymer composition, the polymers being cross-linked polymers selected from at least one of the group consisting of poly(methylvinylether/maleic acid), esters thereof and poly(methyl/vinyl ether/maleic anhydride). The reservoir portion comprises at least one amphipathic component and at least one hydrophobic active agent, wherein in use, on insertion of the microneedles into the stratum corneum of skin, said microneedles swell and said amphipathic component and said at least one hydrophobic active agent diffuse down a concentration gradient from the reservoir layer via the microneedles into the skin.